Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in high-intermediate TMB non-squamous NSCLC
NCT03836066Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- May 2019
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Fundación GECP. Started May 2019; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03836066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836066.